LIFR and its endogenous ligand, LIF, arefrequently overexpressedin many solid tumors, making the LIF/LIFR axis a promising targetfor cancer therapy. This signaling pathwayactivates oncogenic pathways such as JAK/STAT3, MAPK, AKT, and mTOR,contributing to tumor growth, progression, metastasis, stemness, andresistance to therapy. The gene discussed is LIF; the disease is cancer.